Mercado global de medicamentos para o cancro da cabeça e pescoço – Tendências do setor e previsão para 2029

Análise de mercado e insights Mercado global de medicamentos contra o cancro de cabeça e pescoço

Espera-se que o mercado de medicamentos contra o cancro de cabeça e pescoço ganhe crescimento de mercado no período de previsão de 2022-2029. A Data Bridge Market Research analisa o mercado para crescer a um CAGR de 8,65% no período de previsão acima mencionado. O aumento da incidência de cancro de cabeça e pescoço em todo o mundo é o fator vital que aumenta o crescimento do mercado de medicamentos contra o cancro de cabeça e pescoço.

O cancro da cabeça e pescoço é um tipo de cancro que se desenvolve na garganta, laringe, nariz, seios perinasais, lábios, glândulas salivares e boca. Para o tratamento do cancro da cabeça e pescoço, são utilizados vários medicamentos isoladamente ou em associação. Apesar de os medicamentos quimioterápicos tradicionais serem melhor utilizados em conjunto com a radioterapia, as terapias imunológicas dirigidas estão a tornar-se uma opção de tratamento padrão para os cancros de cabeça e pescoço em fase avançada.

O aumento da população geriátrica global impulsionará o crescimento do mercado, assim como o consumo de tabaco e álcool, a sensibilização para o tratamento e o avanço tecnológico, a taxa de iniciativas de investigação e desenvolvimento, a adoção da imunoterapia em vários países, a procura por terapia combinada para a gestão do cancro de cabeça e pescoço e o aumento do número de hospitais provavelmente impulsionarão a taxa de crescimento do mercado.

Além disso, o aumento do número de doentes nas economias atrasadas, um aumento das economias emergentes inexploradas e um aumento do número de medicamentos em pipeline criarão novas oportunidades para o mercado de medicamentos contra o cancro de cabeça e pescoço durante o período de previsão de 2022 -2029.

However, increased treatment costs, an increase in the adverse effects associated with the use of head and neck cancer drugs, and lack of awareness among patients and physicians about head and neck treatment are the major factors acting as restraints, and will further challenge the head and neck cancer drug market during the forecast period.

This head and neck cancer drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the head and neck cancer drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Head and Neck Cancer Drug Market Scope and Market Size

The head and neck cancer drug market is segmented on the basis of treatment type, type, drug type, route of administrations and end-users. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of treatment type, the head and neck cancer drug market is segmented into chemotherapy, targeted therapy, immunotherapy, surgery, radiation therapy, medication and others.
• Based on type, the head and neck cancer drug market is segmented into laryngeal and hypopharyngeal cancer, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, oral and oropharyngeal cancer, salivary gland cancer and others.
• Based on drug type, the head and neck cancer drug market is segmented into carboplatin, cisplatin, docetaxel, paclitaxel, 5-fluorouracil, epirubicin and others.
• Based on route of administration, the head and neck cancer drug market is segmented into oral, radiation and injectable.
• The head and neck cancer drug market is also segmented on the basis of end-users into hospitals, homecare, specialty clinics and others.

Head and Neck Cancer Drug Market Country Level Analysis

Head and neck cancer drug market is analyzed and market size information is provided by the country, treatment type, type, drug type, route of administrations and end-users as referenced above.

The countries covered in the head and neck cancer drug market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

Asia-Pacific would exhibit the highest growth rate for the head and neck cancer drug market due to the presence of major key players, a large population base, an increase in head and neck cancer incidence, and an increase in demand for head and neck cancer combination therapeutics risk factors such as increased alcohol consumption, increased cigarette smoking, and increased tobacco use. In the Asia-Pacific region, betel quid chewing is the most common type of tobacco chewing. Furthermore, an increase in disease awareness and early detection, as well as an increase in healthcare expenditure, drive the growth of the market in this region.

The country section of the head and neck cancer drug market report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Head and neck cancer drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the head and neck cancer drug market report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the head and neck cancer drug market in the growth period.

Competitive Landscape and Global Head and Neck Cancer Drug Market Share Analysis

O panorama competitivo do mercado de medicamentos contra o cancro de cabeça e pescoço fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos , pipelines de ensaios clínicos, aprovações de produtos, patentes, largura e amplitude do produto, domínio da aplicação, curva de segurança da tecnologia. Os dados fornecidos acima estão apenas relacionados com o foco das empresas relacionado com a pesquisa de mercado de medicamentos contra o cancro de cabeça e pescoço.

Alguns dos principais players que operam no mercado de medicamentos contra o cancro da cabeça e pescoço são a AstraZeneca, Immutep, Fortress Biotech, F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, Alimera Sciences, ALLERGAN, Regeneron Pharmaceuticals Inc., Pfizer Inc., Ltd., Oculis, Bayer AG, Bausch & Lomb Incorporated, The National Eye Institute, Medytox, Smith+Nephew, Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., LGM Pharma., Lannett e NorthStar Rx LLC entre outros.

SKU-37163